Merck, Inc.
A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 6
- Registration Number
- NCT00002235
- Locations
- ๐บ๐ธ
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
๐บ๐ธUniv of Colorado / Health Science Ctr, Denver, Colorado, United States
๐บ๐ธPacific Oaks Med Group, Beverly Hills, California, United States
The Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 780
- Registration Number
- NCT00002443
A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT00005921
- Locations
- ๐บ๐ธ
Gary Calandra, Rahway, New Jersey, United States
Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 80
- Registration Number
- NCT00002241
- Locations
- ๐บ๐ธ
Chelsea Village Med Ctr, New York, New York, United States
๐บ๐ธSt Lukes / Roosevelt Hosp / HIV Center, New York, New York, United States
๐บ๐ธUniv of California at San Francisco Gen Hosp, San Francisco, California, United States
The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00005118
- Locations
- ๐บ๐ธ
Chicago Ctr for Clinical Research, Chicago, Illinois, United States
๐บ๐ธBisher Akil, Los Angeles, California, United States
๐บ๐ธInstitute of Human Virology, Baltimore, Maryland, United States
A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 400
- Registration Number
- NCT00002208
- Locations
- ๐บ๐ธ
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
๐บ๐ธJohns Hopkins Hosp, Baltimore, Maryland, United States
๐บ๐ธUniv of Alabama at Birmingham, Birmingham, Alabama, United States
A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 600
- Registration Number
- NCT00002155
- Locations
- ๐บ๐ธ
Merck & Co Inc, Whitehouse Station, New Jersey, United States
A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 350
- Registration Number
- NCT00002406
- Locations
- ๐บ๐ธ
Anderson Clinical Research, Pittsburgh, Pennsylvania, United States
๐บ๐ธBrigham and Women's Hosp, Boston, Massachusetts, United States
๐บ๐ธBoston Med Ctr / Clinical Research Office, Boston, Massachusetts, United States
Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00002375
- Locations
- ๐บ๐ธ
UCSD Treatment Ctr / Dept of Medicine and Pediatrics, San Diego, California, United States
๐บ๐ธUniv of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธUniv of Pittsburgh / Graduate School of Public Health, Pittsburgh, Pennsylvania, United States
A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00002452
- Locations
- ๐บ๐ธ
Hawaii AIDS Clinical Trial Unit, Honolulu, Hawaii, United States
๐บ๐ธCornell Clinical Trials Unit - Chelsea Clinic, New York, New York, United States
๐บ๐ธUniv of Alabama at Birmingham, Birmingham, Alabama, United States